Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers, making them attractive drug targets. Here we have characterized tumour cell responses to two new inhibitors of FGFR1-3, AZ12908010 and the clinical candidate AZD4547, making comparisons with the well-characterized FGFR inhibitor PD173074. In a panel of 16 human tumour cell lines, the anti-proliferative activity of AZ12908010 or AZD4547 was strongly linked to the presence of deregulated FGFR signalling, indicating that addiction to deregulated FGFRs provides a therapeutic opportunity for selective intervention. Acquired resistance to targeted tyrosine kinase inhibitors is a growing problem in the clinic but has not yet been explored for FGFR inhibitors. To assess how FGFRdependent tumour cells adapt to long-term FGFR inhibition, we generated a derivative of the KMS-11 myeloma cell line (FGFR Y373C ) with acquired resistance to AZ12908010 (KMS-11R cells). Basal phosphorylated FGFR and FGFR-dependent downstream signalling were constitutively elevated and refractory to drug in KMS-11R cells. Sequencing of FGFR3 in KMS-11R cells revealed the presence of a heterozygous mutation at the gatekeeper residue, encoding FGFR3 V555M ; consistent with this, KMS-11R cells were crossresistant to AZD4547 and PD173074. These results define the selectivity and efficacy of two new FGFR inhibitors and identify a secondary gatekeeper mutation as a mechanism of acquired resistance to FGFR inhibitors that should be anticipated as clinical evaluation proceeds.
INTRODUCTION
The fibroblast growth factors (FGFs) act via four receptor tyrosine kinases (FGF receptors (FGFRs)) to elicit diverse physiological responses.
1,2 FGFR signalling is important during embryonic development, has been implicated in proliferation, differentiation, angiogenesis and wound repair, and deregulated FGFR signalling is associated with chondrodysplasia and craniosynostosis syndromes. 3 There is growing interest in inhibiting FGFR signalling in cancer. FGFR signalling promotes tumour angiogenesis, and deregulated expression of FGFs can drive tumour cell proliferation, survival and chemoresistance; 4 furthermore, increasing evidence indicates that FGFRs can act as driving oncogenes in certain cancers. 5, 6 FGFRs are deregulated in a variety of cancers, including multiple myeloma (MM), 7 gastric, 8 breast 9 and urothelial 10 cancers due to gene amplification, receptor overexpression and/or activating point mutations.
Translocations can also result in FGFR1 fusion proteins with constitutive kinase activity. 11 Finally, alternative splicing of receptors can sensitize them to FGFs that they would not normally be responsive to. 12 Inappropriate activation of FGFRs and their downstream effector signalling pathways (for example, RAS-RAF-MEK1/2-ERK1/2, phosphoinositide-3 kinase, phospholipase-C gamma (PLCg) and signal transducer and activator of transcription 3 (STAT3)) drives cell proliferation, survival and invasion. 1, 5, 6 Consequently, there is a growing interest in developing FGFR-selective tyrosine kinase inhibitors (TKIs). The success of FGFR inhibitors (FGFRi) will require knowledge of their cellular selectivity, determinants of intrinsic tumour cell sensitivity/resistance and the mechanisms by which tumour cells adapt (acquired resistance). Here we have investigated these issues with two new FGFR TKIs, the clinical lead compound AZD4547 13 and the closely related molecule AZ12908010. In a panel of 16 human cell lines from four cancer types, their biological activity is confined to those cells with deregulated FGFR2 or FGFR3; absence of deregulated FGFR or the presence of other oncogenic drivers (human epidermal growth factor receptor 2 (HER2) or RAS) is associated with intrinsic resistance. Using KMS-11 MM cells, we show for the first time that acquired resistance to FGFRi can arise due to the emergence of a second site FGFR3 V555M gatekeeper mutation, suggesting that such FGFR mutations should be anticipated as clinical evaluation proceeds.
RESULTS

Cellular characterization of AZ12908010
Initially we focused on three new ATP-competitive FGFR TKIs: AZD4547, 13 which has recently entered clinical trials, and AZ12576089 and AZ12908010, which were discovered during the development of AZD4547. AZ12576089 (hereafter AZ6089) exhibits in vitro inhibitory concentration (IC) 50 values of 57, 5, 78 and 435 nM against FGFR1-4, respectively, and causes 470% inhibition of 14 other protein kinases, including cyclin-dependent kinase-2 (CDK2)-cyclin A, YES, SRC and LCK at 1 mM.
14 AZ12908010 (hereafter AZ8010) is more potent than AZ6089 (in vitro IC 50 values of 8, 1 and 17 nM against FGFR1, FGFR2 and FGFR3) and has a more favourable selectivity profile, inducing 70% inhibition of FLT1, IGF1R, YES, TBK1 and CAMKK among 75 other protein kinases.
Initial cellular characterization of AZ6089 and AZ8010 was in FGF-responsive CCl39 fibroblasts 15 (Supplementary Figure 1A) . FGF2-driven cell proliferation was inhibited by 100 nM AZ6089 and abolished by 100 nM AZ8010; the epidermal growth factor receptor inhibitor, AG1478, served as a negative control (Supplementary Figure 1A) . AZ8010 was more potent (IC 50 of B3 nM compared with B30 nM for AZ6089; Supplementary Figure 1B) , consistent with their relative in vitro potencies. FGF2-driven extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation and cyclin D1 expression was abolished by AZ6089 and AZ8010 (Supplementary Figures 1C and D) , whereas responses to thrombin or epidermal growth factor were unaffected ( Supplementary Figures 2A-C) . Some FGFRi, including PD173074, exhibit activity against platelet-derived growth factor receptor (Supplementary Figure 2A) , whereas AZ6089 and AZ8010 had only a marginal effect ( Supplementary Figures 2A and D) .
Assessing the anti-proliferative effects of AZ8010 and AZD4547 in FGFR-dependent tumour cell lines It is anticipated that tumour cells with deregulated FGFR signalling evolve to be 'addicted' to their particular FGFRs, 16 making them more sensitive to FGFRi, thereby providing a therapeutic window. Accordingly, we examined a panel of 16 human tumour cells lines, including multiple myeloma, urothelial, breast and gastric cancer in which FGFRs are deregulated. For each, we first validated them by characterizing FGFR expression/activity and their sensitivity to the established FGFRi PD173074. We then examined their sensitivity to AZ8010 or AZD4547, a highly potent inhibitor of FGFR1, 2 and 3 in vitro (IC 50 values of 0.2, 2.5 and 1.8 nM, respectively) with weaker activity against FGFR4 kinase (IC 50 165 nM).
13 AZD4547 is selective for FGFR versus vascular endothelial growth factor receptor-2 (kinase insert domain receptor) in vitro (IC 50 ¼ 24 nM) and in cells; exhibits excellent selectivity across a range of tyrosine and serine/threonine kinases, including insulin growth factor receptor (42900-fold), CDK2 (450 000-fold) and p38 (450 000-fold); and does not inhibit ALK, CHK1, epidermal growth factor receptor, mitogen-activated protein kinase-1, MEK1, p70S6K, platelet-derived growth factor receptor, protein kinase B (PKB), Src, Tie2 or PI3k at 100 nM. For these studies, we set aside AZ6089 due to lower potency (Supplementary Figure 1) and poorer selectivity. Results with AZ8010 or AZD4547 are described below for each tumour type.
Multiple myeloma High-level FGFR3 expression is seen in MM patients with the t(4;14)(p16;q32) reciprocal translocation, 7 whereas a subset also carry point mutations within FGFR3. 17 KMS-11, KMS-18, OPM2 and H929 cells all contain the t(4;14)(p16.3;q32) translocation and overexpressed FGFR3; MM.1S cells are t(4;14)(p16.3;q32)-negative 18 ( Figure 1a ). The relative expression levels of FGFR3 were consistent with published data. 19, 20 KMS-11, KMS-18 and  OPM2 cells overexpress FGFR3  Y373C , FGFR3  G384D and FGFR3   K650E , respectively, whereas H929 cells express wild-type (WT) FGFR3. 18 FGFR signalling is only partially ligand-independent in KMS-11 and OPM2 cells, and is completely dependent on ligand in KMS-18 cells. 20 Indeed, FGF2 increased phosphorylation of the FGFR substrate, FRS2a, in both KMS-11 and OPM2 cell lines, and this was abolished by PD173074 (Figure 1a) , whereas P-FRS2a was not detected in KMS-18 cells, H929 cells (low levels of WT FGFR3) or MM.1S cells. PD173074 inhibited the proliferation and survival of KMS-11 and OPM2 cells, had a marginal effect on KMS-18 and H929, and had no effect on MM.1S cells (Supplementary Figures 3A and B) .
To test the efficacy of AZ8010, we focused on KMS-11 cells. FGFR3 signalling (phosphorylated FGFR (P-FGFR) and phospho-ERK 1/2 (P-ERK1/2)) was abolished by 10 nM AZ8010 (Figure 1b) , whilst cell proliferation was also inhibited (IC 50 B10 nM) (Figure 1c) . Cells arrested in G1 of the cell cycle within 24 h (Figure 1d) , whereas dead cells (sub-G1 DNA) were observed after 96 h (Figure 1e) . Similar results were observed in OPM2 cells (data not shown) and with PD173074 (Supplementary Figure 3C) . In addition, AZD4547 also inhibited signalling downstream of FGFR3 and blocked the proliferation of KMS-11 cells (see below, Figure 5c ). In all assays, sensitivity to PD173074, AZ8010 or AZD4547 was confined to those cells with deregulated FGFR, but KMS-18 cells were notably less sensitive; the absence of deregulated FGFR (MM.1S) or the presence of NRAS G13N (H929) was associated with resistance to FGFRi.
Urothelial cancer Mutant FGFR3 is found in 60% of low-grade and low-stage urothelial cancer (UC), 10, 21, 22 and in a subtype of high-grade UC, 23 whereas FGFR3 overexpression occurs in both forms. 22 In agreement with published mRNA expression data, 24 FGFR3 protein levels were high in 97-7 cells, moderate in RT4 and RT112 cells, and low in 97-29 and T24 cells ( Figure 2a) ; of these, 97-7 and 97-29 cells express FGFR3 S249C . P-FRS2a was observed in cell lines overexpressing FGFR3 (97-7, RT4 and RT112) but was absent from 97-29 or T24 cells (Figure 2a) . PD173074 inhibited the proliferation of 97-7, RT4 and RT112, causing a G1 cell cycle arrest, but had little effect on 97-29 cells and no effect on T24 cells (Supplementary Figures 4A-C) .
Both AZ8010 and AZD4547 inhibited the proliferation of 97-7 and RT4 cells (Figures 2b and c) . The 97-7 and RT4 cells responded to AZD4547 with a dose-dependent G1 cell cycle arrest with no evidence of cell death (Figure 2d ). In contrast, T24 cells (WT FGFR3, HRAS G12V ) were B100-fold less sensitive to AZ8010 (Figure 2b ) and completely refractory to AZD4547 (Figures 2c and d) . Thus, sensitivity to PD173074, AZ8010 and AZD4547 was confined to those UC cells that exhibited high expression of either mutant (97-7) or WT (RT4, RT112) FGFR3. Low-level expression of FGFR3 S249C (97-29 cells) did not confer strong FGFR dependency, and the absence of deregulated FGFR and the presence of mutant HRAS G12V (T24 cells) was associated with resistance to FGFRi.
Breast cancer
The 8p11-p12 amplicon encompassing FGFR1 is observed in 10-15% breast cancer patients, and a subset of these overexpress FGFR1 protein. 9 Amplification and overexpression of FGFR2 is observed in 4-12% breast tumours, 9 including triple-negative breast cancer, 25 and is associated with poor prognosis. 26 FGFR1 protein was not expressed in Sum52-PE breast cancer cells, whereas FGFR2 was expressed at very high levels 27 ( Figure 3a) , whereas SKBR3 and T47D cells expressed FGFR3, but not FGFR1, FGFR2 or FGFR4 ( Figure 3a) . P-FGFR and P-FRS2a were only detected in Sum52-PE cells (correlating with FGFR2). PD173074 treatment inhibited ERK1/2 phosphorylation ( Figure 3b ) and proliferation of Sum52-PE (Supplementary Figure 5A) causing a G1 cell cycle arrest (Supplementary Figure 5B) ; SKBR3 and T47D cells were unaffected. Thus, Sum52-PE cells were addicted to FGFR activity to maintain P-FRS2a and ERK1/2 activity. Using these cells as a model system, we found that AZ8010 caused a dosedependent inhibition of P-ERK1/2 and P-PKB. Inhibition of both pathways was observed at 10-30 nM (Figure 3c ) within 1 h of treatment ( Figure 3d Gastric cancer FGFR2 amplification, found in the more aggressive diffuse gastric cancer, [28] [29] [30] is observed in B10% of primary GCs. 31 KatoIII and Snu16 cells, which exhibit amplification and overexpression of FGFR2, 32 displayed strong constitutive P-FGFR and P-FRS2a, which were strongly inhibited by AZD4547 ( Figure 4a) ; in contrast, NCI-N87 had normal FGFR2 expression but exhibit HER2 amplification. The strong P-FGFR, P-FRS2a, P-STAT3, P-PLCg, P-PKB and P-ERK1/2 signals in KatoIII and Snu16 cells were abolished by AZD4547 (IC 50 In summary, characterization of 16 tumour cell lines revealed that: (i) sensitivity to AZ8010 and AZD4547 was confined to cells with deregulated FGFR activity, whether due to mutation, translocation or amplification (Table 1) ; (ii) within these, KMS-18 MM and RT112 UC cells were somewhat less sensitive, and (iii) the absence of deregulated FGFR or the presence of alternate oncogenic drivers (NRAS G13N in H929 cells, HRAS G12V in T24 cells or HER2 in NCI-N87 cells) was associated with intrinsic resistance.
Modelling acquired resistance to FGFRi
The success of TKIs, such as gefitinib, erlotinib and imatinib, has been marred by acquired resistance. 33, 34 As new FGFRi enter clinical trials, it is timely to anticipate possible mechanisms of acquired resistance. As clinically relevant resistance mechanisms can be discovered by modelling in cell culture, 34, 35 we generated AZ8010-resistant derivatives of the KMS-11 MM cell line (KMS-11R cells). KMS-11R cells grew at the same rate as parental KMS-11 cells (Supplementary Figure 6A) , were B100-fold resistant to AZ8010 in proliferation assays ( Figure 5a ) and were also resistant in cell death assays (Figure 5b ). KMS-11R cells were not crossresistant to the multi-drug resistance transporter substrates cisplatin, etoposide and paclitaxel (Supplementary Figure 6B) , arguing against a role for drug efflux pumps. Figure 6C) , suggesting an 'ontarget' resistance mechanism. KMS-11R exhibited elevated basal P-FGFR, P-FRS2a and P-ERK1/2, and these markers were unaffected by AZ8010, except at 1 mM, where P-FRS2a was partially inhibited (Figure 6a ). AZ8010-dependent changes in the expression of cyclin D1, D2 and p27 KIP1 in KMS-11 cells were not observed in KMS11-R cells. Similar results were seen with AZD4547 ( Figure 6b) ; basal P-FRS2a, P-ERK1/2, P-PKB, P-PLCg and P-STAT3 were constitutively upregulated and non-responsive to drug in the KMS-11R cells compared with parental KMS-11 cells. The proapoptotic protein BIM EL , which is phosphorylated and inactivated by ERK1/2, 36,37 was hypo-phosphorylated and increased in abundance when KMS-11 cells were treated with AZD4547, whereas it was constitutively phosphorylated and drug refractory in KMS-11R cells. The increase in P-FGFR and FGFR signalling in KMS-11R cells was not due to increased expression of FGFR3 (Figure 6a ) or other FGFRs (Figure 6c ).
KMS-11R cells were cross-resistant to AZD4547 (Figures 5c and d) and PD173074 (Supplementary
Gatekeeper mutations in several tyrosine kinases confer increased activity as well as being drug refractory. 38 Sequencing confirmed that both KMS-11 and KMS-11R contained the FGFR Y373C mutation (Figure 7a ), but we also found a heterozygous mutation encoding FGFR V555M in KMS-11R cells that was not Figure 7c , upper panels); mutations at this site frequently impart resistance to TKIs. [38] [39] [40] As residues comprising the ATP-binding pocket are completely conserved among FGFR1-3, with the exception of Ala559 in FGFR3 (see Methods), we used the structure of PD173074 in complex with FGFR1 to model this mutation. 41 Our model suggests that Met, with a B25% bulkier side-chain, will restrict access to the cavity adjacent to the adenine ring-binding region (shown in yellow in Figure 7c , lower panel). In particular, the equivalent residue of FGFR1, Val561, makes van der Waals contact with the PD173074, 41 whereas the bulkier side chain of Met561 would disrupt binding of PD173074 (Figure 7c , lower panel). Taken together, our results suggest that a secondary gatekeeper mutation accounts for acquired resistance to AZ8010, AZD4547 and PD173074 in KMS-11R cells.
Genome-wide mRNA expression analysis identifies genes involved in myeloid differentiation and myeloma survival in KMS-11R cells To identify changes in gene expression between KMS-11 and KMS-11R cells, we conducted genome-wide mRNA expression analysis using Human Illumina bead arrays. Candidate genes were selected on the basis of a false discovery rate of o0.05 and an absolute change of at least two-fold (Table 2) . From this list, five (RUNX1T1, PAPSS2, SPINT2, LDCO1L and CEBPA) were validated by quantitative reverse-transcription PCR (qRT-PCR). Interleukin-6 receptor-a (IL6Ra) expression was also elevated in KMS-11R cells and although not considered significant by the above criteria, it was also analysed by qRT-PCR. In all cases, the pattern of expression in the qRT-PCR (Figure 8 ) was consistent with that in the arrays: PAPSS2, SPINT2, LDOC1L and CEBPA were downregulated in KMS-11R cells relative to KMS-11, whereas RUNX1T1 (runt-related transcription factor 1 translocated to 1) and IL6R were both upregulated. Notably, RUNX1T1, IL6R and CEBPA are implicated in leukaemias and myeloma.
DISCUSSION
The incidence of FGFRs as oncogenic drivers in certain forms of cancer has prompted the search for new, selective FGFRi. AZD4547 has recently entered clinical trials, and its biochemical and biological activity in three FGFR-dependent tumour cell lines, including tumour xenograft studies, was recently reported. 13 To broaden this analysis, we used a more diverse panel of 16 human tumour cell lines, representing four tumour types wherein FGFR deregulation is common, and also expanded our analysis to include the related compound AZ8010, providing a richer FGFRbased pharmacology. We also examined the issue of acquired resistance to FGFRi. Deregulated FGFR2 or FGFR3 confers sensitivity to FGFRi: oncogene addiction and therapeutic opportunity Genetic ablation of FGFR3 S249C in 97-7 cells 24 and anti-FGFR3 antibody treatment of OPM2 and KMS-11 cells 42 supports the suggestion that tumour cells evolve to become addicted to their deregulated FGFRs. Our results using AZD4547, AZ8010 and PD173074 provide further strong support for the notion that such 'oncogene addiction' 16 provides an opportunity for tumourselective intervention by FGFRi. Irrespective of tumour type, the 16 cell lines we studied could be divided into: (i) those that were very sensitive to FGFRi; (ii) those that were moderately sensitive to FGFRi, and (iii) those that were completely resistant to FGFRi. All those that were very sensitive exhibited high expression of WT or mutant FGFR2 or FGFR3 and have presumably evolved to be addicted to signalling by these receptors for proliferation and survival. The sensitivity of KG1a cells (FGFR1 gene fusion) to AZD4547 indicates that this also applies to FGFR1. 13 These results underline the exquisite dependency of these cells upon their oncogenic FGFRs (FGFR addiction) and the extent to which this provides a therapeutic opportunity for selective intervention by an FGFRi such as AZD4547. Similar results have been reported for other novel FGFRi. 43 The reduced sensitivity of KMS-18 cells agrees with previous reports wherein FGFR G384D failed to transform NIH3T3 cells 20 and KMS-18 were less sensitive to the TKI CHIR-258/dovitinib. 44 Clearly, FGFR3 mutations are graded in terms of their activation capability and this determines the degree of addiction and sensitivity to FGFRi. The moderate sensitivity of RT112 cells contrasts with a recent report; 45 this may reflect differences in assays for proliferation/viability. For example, we employed a 24-h assay, whereas Lamont et al. 45 used a 5-day assay and even the moderately sensitive KMS-18 cells responded to the FGFRi after 7 days of drug treatment. 18 All cells that were insensitive lacked deregulated FGFR and presumably have not evolved any dependence upon FGFR signalling. Tumour cell responses to FGFRi were also correlated with the presence of intrinsic resistance factors, such as alternative oncogenic drivers (HER2 in NCI-N87, NRAS G13N in H929 and HRAS G12V in T24 cells). FGFR3 or RAS mutations are mutually exclusive in UC, 46 and as mutant RAS activates many of the same effector pathways, it may circumvent the requirement for FGFR Acquired resistance to FGFRi arising from a gatekeeper mutation in FGFR3 Acquired resistance to TKIs can arise through multiple mechanisms. [33] [34] [35] KMS-11R cells with acquired resistance to AZ8010 were cross-resistant to AZD4547 and PD173074, and sequencing revealed a point mutation at the gatekeeper residue (FGFR3 V555M ). Gatekeeper mutations typically inhibit drug binding in the ATP-binding site and also increase the activity of the kinase domain by facilitating assembly of an enzymatically active kinase conformation. 38 Indeed, FGFR1 V561M exhibits a higher level of auto-phosphorylation. 48 Our results indicate that FGFR3 can also be 'activated' as well as being rendered drugresistant by a gatekeeper mutation. Although gatekeeper mutations in FGFRs have previously been engineered, 48 we believe this is the first instance of their emergence in any FGFR by drug selection and suggests that this mechanism of resistance to FGFRi should be anticipated as clinical evaluation proceeds, perhaps through the development of second-generation inhibitors or covalent FGFRi. 39, 48 A number of TKIs that inhibit FGFR are currently in development, including mixed kinase inhibitors, such as CHIR-258/ dovitinib, 44 brivanib alaninate 49 and BIBF-1120, 50 wherein FGFR may not be the dominant pharmacology. As these compounds progress, it will become increasingly important to understand their primary targets to interpret clinical trial results. Our analysis across a panel of cell lines suggests that AZD4547 is an FGFRselective small molecule inhibitor, and in vitro pharmacology and lack of effect on vascular endothelial growth factor receptor-2-dependent markers in vivo 13 are consistent with this. The demonstration that KMS-11R cells with the FGFR3 V555M gatekeeper mutation are 100-fold resistant to AZD4547, AZ8010 and PD173074 provides further strong genetic evidence that the primary target of these compounds in this system is indeed FGFR3.
Deregulated expression of IL6R, RUNX1T1 and CEBPA in KMS-11R cells Among the changes in gene expression associated with FGFR3 Y373C;V555M in KMS-11R cells (Table 2 and Figure 8 ), three are of particular note. CEBPA encodes CCAAT/enhancer binding protein-a, a tumour suppressor that promotes myeloid cell differentiation. The CCAAT/enhancer binding protein-a is inactivated or downregulated in leukaemias and myeloma, and its reexpression restores their differentiation programme.
51 RUNX1T1 (also called ETO) encodes a transcriptional repressor, which is fused to RUNX1 (AML1) in 8q22;21q22 translocation-positive acute myeloid leukaemia. The resulting RUNX1/RUNX1T1 (AML1-ETO) fusion gene is an oncogene that promotes leukaemic progression. Interestingly, RUNX1-RUNX1T1 downregulates CEBPA expression, 52 raising the possibility that the decrease in CEBPA in KMS-11R cells might be linked to the increase in RUNX1T1. Finally, IL-6 promotes myeloma proliferation and survival 53 so that the increase in IL6R expression in KMS-11R cells might facilitate IL6 signalling in these cells. It is notable that three genes implicated in myeloid malignancies are deregulated in KMS-11R cells and future experiments should aim to address how they are regulated by FGFR3 Y373C;V555M signalling and their role, if any, in FGFRi resistance in KMS-11R cells. For example, RUNX1T1 is also overexpressed in imatinib-resistant chronic myeloid leukaemia cells. 54 In summary, the biological activity of two new FGFRi, AZ8010 and AZD4547, is confined to tumour cells with deregulated FGFR2, FGFR3 (herein) and FGFR1. 13 The absence of deregulated FGFR or the presence of other driving oncogenes (for example, HER2, NRAS or HRAS) is associated with intrinsic resistance. These results support the hypothesis that FGFR addiction provides a window for selective therapeutic intervention and highlights the efficacy and selectivity of these new compounds. We also show for the first time that acquired resistance to FGFRi can arise through the emergence of gatekeeper mutations in FGFR3. This in turn provides further genetic evidence of the FGFR-selective effects of AZ8010 and AZD4547, and suggests that gatekeeper mutations should be anticipated and planned for as clinical trials progress.
MATERIALS AND METHODS
Cells and routine cell culture
Culture of CCl39 fibroblasts was described previously. 55 Inhibitors and growth factors AZ6089, AZ8010, AZD4547 13 and Selumetinib/AZD6244 (Sel) 56 were provided by AstraZeneca, Alderley Park, UK. PD173074, AG1478, FGF2, PDGF-AA, thrombin and epidermal growth factor were purchased from Calbiochem, Feltham, UK.
Preparation of cell extracts and western blotting
Cells were lysed in TG lysis buffer, harvested and cell extracts fractionated by SDS-polyacrylamide gel electrophoresis as described previously. 36, 55 Antibodies used for western blotting were from Santa Cruz Biotechnology Assays of cell proliferation, cell cycle and cell death [ 3 H]thymidine incorporation was assayed as described previously, 55 except for non-adherent cells, which were harvested on to Unifilter plates (Perkin Elmer, Cambridge, UK) using a TomTec harvester (Hamden, CT, USA) before scintillation counting. Distribution of cells in G1, S or G2/M and dead cells (sub-G1) was determined by propidium iodide staining and flow cytometry. 55 Generation of drug-resistant KMS11 cells Cells in exponential growth phase were exposed to 30 nM AZ8010. After 4 days, they were passaged (1:3) into fresh medium containing 30 nM AZ8010 and 3 days later, the drug concentration was increased to 100 nM. AZ8010 dose was increased incrementally up to 3 mM, which took 11 weeks. Resistant cells were then maintained in 3 mM AZ8010 and named 'KMS-11R' cells.
Modelling the impact of the FGFR3 V555M mutation on PD173074 binding to the ATP-binding pocket, based on the FGFR1:PD173074 structure Sequence alignment of FGFR1-3 employed Jalview. 57 Residues in the ATP-binding pocket that contact the inhibitor PD173074 and second tier residues were identified from the crystal structure of the complex (2fgi.pdb) 41 by measuring proximity of surrounding residues to PD173074 using the programme PyMOL (www.pymol.org). These 65 residues were almost completely conserved among the three FGFR proteins. Notably, pocket residues equivalent to Ala559 in FGFR1 and FGFR2 (Ser565 and Ser568, respectively) contribute to the pocket surface only via their mainchain h side-chain. Modelling mutation of FGFR1 residue Val561 to Meth, equivalent to the FGFR3 Val555Met, used the FGFR1:PD173074 crystal structure and electron density map (2fgi.pdb) and the programme COOT. 58 The rotamer of the methione that did not clash with surrounding residues was chosen for the model. Surface and cartoon renderings of the PD173074-binding pocket were made using the programme PyMOL (www.pymol.org). Analysis of differentially expressed genes was performed on RNA extracted from KMS-11 and KMS-11R cells (biological triplicates for each cell line) using Illumina bead arrays (ArrayExpress database, E-TABM-1222). Raw data was normalized using the Genespring programme, and genes were selected on the basis of a corrected (Benjamini and Hochberg) P-value of o0.05 and an absolute change of at least two-fold. Genes that were deemed interesting for further validation by qRT-PCR ( Figure 8 ) are highlighted in bold with an asterisk (*). (Table 2) were selected on the basis of a false discovery rate of o0.05 59 and an absolute change of at least two-fold. Microarray data are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under accession number E-TABM-1222.
Quantitative reverse-transcription PCR RNA was isolated from KMS-11 and KMS-11R cells and converted to cDNA by using the Applied Biosystems Reverse Transcription kit (Applied Biosystems). The cDNA was then used as a template in a qPCR reaction with SYBER green (Applied Biosystems) and primers to amplify the specific gene products. Mean expression values of glyceraldehyde-3-phosphate dehydrogenase and ribosomal protein L13A were used to normalize target gene transcript levels. 60 Primers used were: Glyceraldehyde-3-phosphate dehydrogenase, forward: 
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